RG 6061

Drug Profile

RG 6061

Alternative Names: EZN-2968; RG6061; RO-7070179; SPC-2968

Latest Information Update: 10 Dec 2015

Price : $50

At a glance

  • Originator Santaris Pharma
  • Developer Enzon Pharmaceuticals; Roche
  • Class Antineoplastics; Antisense oligoribonucleotides
  • Mechanism of Action Hypoxia-inducible factor-1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatocellular carcinoma; Solid tumours
  • Suspended Lymphoma

Most Recent Events

  • 01 Nov 2015 Phase-I clinical trials in Hepatocellular carcinoma (Second-line therapy or greater) in USA (IV)
  • 01 Oct 2015 Hoffmann-La Roche plans a phase Ia trial for Liver cancer in USA (NCT02564614)
  • 01 Sep 2013 National Cancer Institute completes a phase I trial in Liver Cancer in USA (NCT01120288)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top